Clinical prognostic prediction of MMP13 expression in head and neck squamous cell carcinoma using contrast-enhanced computed tomography radiomics: a model development and validation study

利用对比增强CT放射组学预测头颈部鳞状细胞癌中MMP13表达的临床预后:模型开发与验证研究

阅读:2

Abstract

BACKGROUND: Annually, more than 550,000 people are diagnosed with head and neck squamous cell carcinoma (HNSCC) using invasive techniques, emphasizing the need for non-invasive diagnostic methods. Thus, our investigation aimed to create radiomics models that could forecast patients' MMP13 expression levels. METHODS: This study was based on downloading genomic data and enhanced computed tomography (CT) images of HNSCC patients from The Cancer Imaging Archive (TCIA) and The Cancer Genome Atlas (TCGA) databases for prognostic analyses, image feature extraction, and construction of the radiomics models. Survival analysis (Kaplan-Meier survival curve, COX regression analysis, subgroup analysis, and interaction test) was used to explore the prognostic value of MMP13 in HNSCC. Correlation analysis, differential analysis of immune cell infiltration and enrichment analysis were used to explore the potential molecular mechanisms of CXCL8 expression and its relationship with the immune microenvironment. Radiomics models were constructed and Rad-score-based prediction of MMP13 and epithelial-mesenchymal transition (EMT) expression in HNSCC tissues was performed. Finally, intraclass correlation coefficient (ICC) was used to evaluate the consistency of radiomics features. RESULTS: TCGA had a total of 483 HNSCC patients, of which high (n=326) and low (n=157) MMP13-expressing groups were used in the survival analysis. The MMP13 high-expression and low-expression groups had respective median survival times of 36.43 and 65.73 months. Tumors expressed MMP13 at a substantially greater level than normal tissue. We established the Gradient Boosting Machine (GBM) model and the logistic regression (LR) model, respectively. The area under the curve (AUC) value in the training set was 0.864 (GBM) and 0.746 (LR), and in the validation set was 0.79 (GBM) and 0.73 (LR). The Hosmer-Lemeshow goodness-of-fit test and calibration curve both showed consistency (P>0.05) between the true and predicted values in GBM model. The decision curve analysis (DCA) display model exhibited good clinical practicality in both models. CONCLUSIONS: A noteworthy association was observed between MMP13 expression and the prediction of HNSCC. Predicting MMP13 expression levels may be accomplished with the use of radiomics, which is based on contrast-enhanced computed tomography (CECT).

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。